Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 2
2014 pubmed 10 citations

Intrarenal ghrelin receptor antagonism prevents high-fat diet-induced hypertension in male rats.

Kemp. Brandon A BA; Howell. Nancy L NL; Gildea. John J JJ; Padia. Shetal H SH

Key Findings

  • High‑fat diet raises renal GHSR expression and sodium reabsorption, leading to hypertension in rats.
  • Intrarenal infusion of a GHSR antagonist ([D‑Lys‑3]‑GHRP‑6) or an inverse agonist prevents the development of hypertension.
  • The protective effect is due to blocking the constitutive (always‑on) activity of GHSR, not changes in circulating ghrelin.

Practical Outcomes

  • For biohackers using GHRP‑6 to boost growth hormone, chronic use might increase kidney sodium retention and raise blood pressure, especially on a high‑fat diet. Monitoring blood pressure and limiting high‑fat intake are prudent. While GHSR antagonists show promise for blood‑pressure control, they are not yet ready for human use.

Summary

In rats fed a high‑fat diet, the kidney's ghrelin receptor (GHSR) becomes more active, causing the kidneys to hold onto sodium and raise blood pressure. Blocking this receptor with a specific peptide (a GHRP‑6 variant) stopped the rise in blood pressure, showing that the receptor's activity—not the hormone level itself—drives the problem.

Abstract

Excess weight gain contributes up to 65% of the risk of primary hypertension, and the increase in blood pressure in response to high-fat diet (HFD) is preceded by significant increases in renal tubular sodium (Na(+)) reabsorption. In normal rats, intrarenal ghrelin infusion increases distal nephron-dependent Na(+) reabsorption via activation of the intrarenal ghrelin receptor (GHSR). This study focusses on the role of intrarenal GHSR-mediated Na(+) reabsorption in HFD-induced hypertension. Dahl salt-sensitive rats received standard diet or HFD for 6 weeks. Rats underwent uninephrectomy and osmotic minipump implantation for chronic intrarenal delivery of vehicle (0.25 μL/h × 28 d), selective GHSR antagonist [D-Lys-3]-growth hormone releasing peptide-6 (0.2μM/d), or GHSR inverse agonist [D-Arg(1), D-Phe(5), D-Trp(7,9), Leu(11)]-substance P (SUB-P) (3.6μM/d). HFD rats with vehicle pumps had significantly increased renal GHSR expression compared with standard diet (0.092 ± 0.005 vs 0.065 ± 0.004 arbitrary units; P < .05), whereas acyl ghrelin levels were similar (16.3±6.2 vs 15.7±8.7 pg/g tissue). HFD rats with vehicle pumps became hypertensive after 2 weeks (P < .05) and showed a significant reduction in 24-hour urine Na(+) before hypertension. At this time, these rats showed an increase in collecting duct α-epithelial Na(+) channel, thereby providing a potential mechanism for the excess Na(+) reabsorption. In contrast, HFD rats with [D-Lys-3]-growth hormone releasing peptide-6 or SUB-P pumps never became hypertensive and did not show the reduction in urine Na(+). Because SUB-P blocks the constitutive, but not ghrelin-dependent, activity of the GHSR, and HFD-induced α-epithelial Na(+) channel up-regulation was abolished during GHSR antagonism, these data suggest that HFD increases the constitutive activity of renal GHSR to increase Na(+) reabsorption and induce hypertension in rats.

Study Information

Provider

pubmed

Year

2014

Date

2014-05-05T00:00:00.000Z

DOI

10.1210/en.2013-2177

Citations

10

References

44